Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Onc promotional data, my read fwiw
View:
Post by canadafan on Dec 11, 2022 3:52pm

Onc promotional data, my read fwiw

So, Onc puts out a very informative & understandable article.
Some call it self promotion ( in a derogatory context).
Perhaps the same complainers who say " management needs to communicate better".
imho that publication is great communication.
" self promotion" ?
Absolutely, something has to be done to counter the collection of hard working bashing crew.
Who at every turn possible try to discredit anything good out of onc.
For those who missed it, I'll republish later.
bottom line, it does a great jo/ at explaining the trials,the management depth,recent developments & upcoming expectations.
Not to mention the average analyst target I think near $7. With high being $15 & low being $6.
I could be wrong on numbers. Regardless, WAY more than where we are now.
BTW, all of the information oin the article is founD on company web site. With the exception of the analysts target prices.
Comment by lonc17 on Dec 11, 2022 4:41pm
Buyer beware, Canadafan.  There have been many instances in the past when these advertisments have been used soley to pump ONC's ATM.  The worst culprit of all is Edison Investment Research.  The moment that ONC buys another of their "research" reports will a sad day for the company. Becuase it will tell us with certaninty that ONC has been rejected by ...more  
Comment by westcoast1000 on Dec 11, 2022 5:02pm
ionc, The ATM is how this company has stayed solvent and managed to ride the wave of I/O science and the slow completion of trials to get us here. So I do not begrudge them that. It was the ATM or ....what exactly, other than bankruptcy? Your point that these pieces imply ONCY has been rejected by potential partners is itself a big assumption. That assumption does not follow with certainty ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities